Efficacy and cytokines of lenalidomide therapy in Japanese patients with relapsed or refractory multiple myeloma

Trial Profile

Efficacy and cytokines of lenalidomide therapy in Japanese patients with relapsed or refractory multiple myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2012

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 20 Nov 2012 Planned end date added as reported by University Hospital Medical Information Network - Japan.
    • 08 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top